explore -WSS

explore

author：knowledge 2025-09-30 15:16:02 - browse：372

Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease.

Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed reductions in LDL-C levels of 39%, 48%, and 55%, respectively. The latter patient’s decline in so-called “bad” cholesterol was maintained for six months.

The Verve-101 study results were presented at the American Heart Association conference and are the first data in patients from a therapy that uses base editing to change individual letters of DNA. Verve licensed the base-editing technology from Beam Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Wikipedia

WSS

Christmas in the PICU brings some surprising joy

What STAT readers think about the FDA and patient advocacy

Bristol Myers buys into radiopharmaceuticals with RayzeBio

WATCH: Why do bright lights make us see spots?

Food makers tried to stack nutrition panel with preferred experts

Medicare Advantage beneficiaries sue Humana over algorithm use

Wikipedia

explore

focus

How one medical school became remarkably diverse

FDA panel endorses Alnylam’s heart drug — after picking it apart

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

HCA sued by state AG for quality issues at Mission Health

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Regeneron agrees to White House price limits on anti

Medicare proposal to cover medical devices draws a mixed reaction

In Spain, a hospital brews its own CAR

entertainment

What to make of Biden’s latest efforts on cancer research

White House touts steps to stem shortages of cancer treatments

IRA could hurt research into orphan drugs for rare diseases

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Long Covid needs a new name — and a new frame

A common UTI test for kids haunts adults as a traumatic 'nightmare'

focus

Wikipedia

focus

explore